NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that management will be participating in the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. Management will be presenting a corporate overview and will be holding one-on-one meetings with investors. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertical

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2025, to holders of record at the close of business on April 4, 2025. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's h

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced it is integrating with LillyDirect pharmacy provider, Gifthealth, to offer streamlined access of single-dose vials of Lilly's prescription obesity treatment Zepbound® (tirzepatide) to eligible LifeMD patients. Integration with the LillyDirect® self-pay pharmacy channel will provide a seamless solution to a patient's Zepbound fulfillment journey while continuing to offer more accessible pricing and direct shipment to patients. LifeMD's comprehensive weight management offering provides a turnkey solution for patients seeking clinical care to lose weig

Lake Street initiated coverage of LifeMD with a rating of Buy and set a new price target of $12.00

Mizuho initiated coverage of LifeMD with a rating of Neutral and set a new price target of $7.00

B. Riley Securities resumed coverage of LifeMD with a rating of Buy and set a new price target of $11.00

4 - LifeMD, Inc. (0000948320) (Issuer)

4 - LifeMD, Inc. (0000948320) (Issuer)

4 - LifeMD, Inc. (0000948320) (Issuer)

4 - LifeMD, Inc. (0000948320) (Issuer)

10-K - LifeMD, Inc. (0000948320) (Filer)

8-K - LifeMD, Inc. (0000948320) (Filer)

S-8 - LifeMD, Inc. (0000948320) (Filer)

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind

NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno

NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy. "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Exec

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2025, to holders of record at the close of business on April 4, 2025. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's h

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on March 10, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 10thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-225-9448International Dial-In:203-518-9708Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy servi

Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Revenue of $119.0 million, with revenue per active earning coach of $4,391 Independent active earning OPTAVIA coaches of 27,100 Net income of $0.8 million (non-GAAP adjusted net income of $1.1 million) Earnings per diluted share ("EPS") of $0.07 (non-GAAP adjusted EPS of $0.10) Cash, Cash Equivalents, and Investment Securities of $162.3 million and no debt Full Year 2024 Revenue of $602.5 million Net income of $2.1 million (non-GAAP adjusted net i

SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

SC 13G - LifeMD, Inc. (0000948320) (Subject)